home / stock / slncf / slncf quote
Last: | $7.60 |
---|---|
Change Percent: | -21.43% |
Open: | $8.5 |
Close: | $7.60 |
High: | $8.5 |
Low: | $7.5 |
Volume: | 2,020 |
Last Trade Date Time: | 07/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.6 | $8.5 | $7.6 | $8.5 | $7.5 | 2,020 | 07-18-2024 |
$7 | $8.45 | $7 | $8.5 | $7 | 8,534 | 07-17-2024 |
$8.37 | $8.5 | $8.37 | $9 | $8.37 | 1,650 | 07-16-2024 |
$8.95 | $10.3 | $8.95 | $11 | $8 | 6,456 | 07-15-2024 |
$14.73 | $14.75 | $14.73 | $14.75 | $10.25 | 1,119 | 07-12-2024 |
$10.25 | $8.94 | $10.25 | $14.75 | $8.33 | 1,876 | 07-11-2024 |
$8.95 | $9 | $8.95 | $9.25 | $8.95 | 3,250 | 07-10-2024 |
$7.5 | $7.5 | $7.5 | $7.5 | $7.5 | 4,215 | 07-09-2024 |
$7 | $7 | $7 | $7 | $7 | 428 | 07-08-2024 |
$6 | $0 | $6 | $0 | $0 | 20 | 07-05-2024 |
$6 | $6 | $6 | $6 | $6 | 100 | 07-02-2024 |
$6.5 | $6.5 | $6.5 | $6.5 | $6.5 | 1,500 | 06-26-2024 |
$6.5 | $0 | $6.5 | $0 | $0 | 22 | 06-24-2024 |
$6.5 | $6.5 | $6.5 | $6.5 | $6.5 | 650 | 06-14-2024 |
$6.01 | $6.01 | $6.01 | $6.01 | $6.01 | 110 | 06-13-2024 |
$7.12 | $0 | $7.12 | $0 | $0 | 45 | 06-11-2024 |
$7.12 | $7.12 | $7.12 | $7.12 | $7.12 | 1,000 | 06-10-2024 |
$7.1 | $7.65 | $7.1 | $8.7 | $7.1 | 1,510 | 06-07-2024 |
$7.6 | $7.6 | $7.6 | $7.6 | $7.6 | 698 | 05-30-2024 |
$7.5 | $7.5 | $7.5 | $7.5 | $7.5 | 500 | 05-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...